Gastrointestinal specialty pharma AGI Therapeutics has assembled a pipeline of six products, four of which are in Phase II trials. It is concentrating most of its efforts in functional GI disorders--IBS, functional dyspepsia and diarrhea, but its portfolio also includes a controlled-release proton pump inhibitor for a niche of the GERD market. In addition, it has an early-stage program in inflammatory bowel disease.

Summarizing the month in European dealmaking.